These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

451 related items for PubMed ID: 22336375

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy.
    Ginj M, Chen J, Walter MA, Eltschinger V, Reubi JC, Maecke HR.
    Clin Cancer Res; 2005 Feb 01; 11(3):1136-45. PubMed ID: 15709181
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy.
    Gabriel M, Oberauer A, Dobrozemsky G, Decristoforo C, Putzer D, Kendler D, Uprimny C, Kovacs P, Bale R, Virgolini IJ.
    J Nucl Med; 2009 Sep 01; 50(9):1427-34. PubMed ID: 19690033
    [Abstract] [Full Text] [Related]

  • 7. Biodistribution and first clinical results of 18F-SiFAlin-TATE PET: a novel 18F-labeled somatostatin analog for imaging of neuroendocrine tumors.
    Ilhan H, Lindner S, Todica A, Cyran CC, Tiling R, Auernhammer CJ, Spitzweg C, Boeck S, Unterrainer M, Gildehaus FJ, Böning G, Jurkschat K, Wängler C, Wängler B, Schirrmacher R, Bartenstein P.
    Eur J Nucl Med Mol Imaging; 2020 Apr 01; 47(4):870-880. PubMed ID: 31492994
    [Abstract] [Full Text] [Related]

  • 8. Preliminary PET/CT Imaging with Somatostatin Analogs [68Ga]DOTAGA-TATE and [68Ga]DOTAGA-TOC.
    Satpati D, Shinto A, Kamaleshwaran KK, Sarma HD, Dash A.
    Mol Imaging Biol; 2017 Dec 01; 19(6):878-884. PubMed ID: 28349291
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. 68Ga/177Lu-labeled DOTA-TATE shows similar imaging and biodistribution in neuroendocrine tumor model.
    Liu F, Zhu H, Yu J, Han X, Xie Q, Liu T, Xia C, Li N, Yang Z.
    Tumour Biol; 2017 Jun 01; 39(6):1010428317705519. PubMed ID: 28618966
    [Abstract] [Full Text] [Related]

  • 12. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals.
    Wild D, Schmitt JS, Ginj M, Mäcke HR, Bernard BF, Krenning E, De Jong M, Wenger S, Reubi JC.
    Eur J Nucl Med Mol Imaging; 2003 Oct 01; 30(10):1338-47. PubMed ID: 12937948
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [(99m)Tc]Demotate 2 in the detection of sst(2)-positive tumours: a preclinical comparison with [(111)In]DOTA-tate.
    Maina T, Nock BA, Cordopatis P, Bernard BF, Breeman WA, van Gameren A, van den Berg R, Reubi JC, Krenning EP, de Jong M.
    Eur J Nucl Med Mol Imaging; 2006 Jul 01; 33(7):831-40. PubMed ID: 16568203
    [Abstract] [Full Text] [Related]

  • 15.
    Zhang H.
    ; 2004 Jul 01. PubMed ID: 20641372
    [Abstract] [Full Text] [Related]

  • 16. Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy.
    Sainz-Esteban A, Prasad V, Schuchardt C, Zachert C, Carril JM, Baum RP.
    Eur J Nucl Med Mol Imaging; 2012 Mar 01; 39(3):501-11. PubMed ID: 22183108
    [Abstract] [Full Text] [Related]

  • 17. Normal uptake of 68Ga-DOTA-TOC by the pancreas uncinate process mimicking malignancy at somatostatin receptor PET.
    Jacobsson H, Larsson P, Jonsson C, Jussing E, Grybäck P.
    Clin Nucl Med; 2012 Apr 01; 37(4):362-5. PubMed ID: 22391705
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-LAN PET/CT imaging in the same patient group with neuroendocrine tumours: preliminary results.
    Demirci E, Ocak M, Kabasakal L, Araman A, Ozsoy Y, Kanmaz B.
    Nucl Med Commun; 2013 Aug 01; 34(8):727-32. PubMed ID: 23728519
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.